• By ICR Secretariat
  • Posted Tuesday, June 20, 2017

Quintiles joins NHS Vanguard's Real World Data Initiative


QuintilesIMS has entered into a strategic collaboration with the national Cancer Vanguard to contribute its anonymised patient level, real world data on drug usage treatment costs and outcomes to extend the capabilities of the body. 


QuintilesIMS was one of four companies so far selected through the NHS Cancer Vanguard Pharma Challenge. Amgen and Sandoz are two of the other companies selected. The Cancer Vanguard works across a total population of 10.7 million people, aiming to transform and create new models of cancer care that can be reproduced nationally.